Pancreatic cancer “is one of the leading causes of cancer death in the United States, partially because 80% of cases are diagnosed at an advanced stage.” Researchers at the University of Texas MD Anderson Cancer Center have “discovered a novel immunotherapy combination, targeting checkpoints in both T cells and myeloid suppressor cells, that successfully reprogrammed the tumor immune microenvironment (TIME) and significantly improved anti-tumor responses in preclinical models of pancreatic cancer.” While more research needs to be done, these initial results are encouraging because there haven’t been effective treatment options for pancreatic cancer.